Disclosed herein are pyrrolopyrimidine derivatives of formula VIII where the substituents are as defined herein, pharmaceutical compositions containing them, and the use of the compounds in the manufacture of medicaments for the treatment of proliferation disorders and other diseases related to the dysregulation of kinases (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAKl, JAK2, JAK3, TEC and TXK) and/or the respective pathways. Specific examples of the compounds of formula VIII include N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide and N-(3-(2-( 4-(1-(2-fluoroethyl)azetidin-3-ylamino)-2-methoxyphenylamino )-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)phenyl)acrylamide.
